Treatment-Related Mortality With Everolimus in Cancer Patients
Robert Wesolowski(The Ohio State University Wexner Medical Center), Erin Macrae(McGill University), Mahmoud Abdel‐Rasoul(The Ohio State University), Charles L. Shapiro(Tisch Hospital), Maria Paskell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maryam B. Lustberg(Yale Cancer Center)
Cited by 17
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
|JAMA|2017|357
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296
Triple-negative breast cancer: promising prognostic biomarkers currently in development
|Expert Review of Anticancer Therapy|2020|236